| Literature DB >> 26613030 |
Kotaro Haruhara1, Nobuo Tsuboi1, Kentaro Koike1, Go Kanzaki1, Yusuke Okabayashi1, Yoichi Miyazaki1, Tetsuya Kawamura1, Makoto Ogura1, Takashi Yokoo1.
Abstract
BACKGROUND: Few studies have been conducted to assess the ambulatory blood pressure (ABP) in IgA nephropathy (IgAN) patients. This study aimed to determine the relationships between ABP and renal histopathological findings assessed using the Oxford classification (OC) and the Japanese classification (JC), which have recently established histopathological criteria for IgAN.Entities:
Keywords: IgA nephropathy; Oxford classification; ambulatory blood pressure; renal biopsy; tubulointerstitial fibrosis
Year: 2015 PMID: 26613030 PMCID: PMC4655792 DOI: 10.1093/ckj/sfv083
Source DB: PubMed Journal: Clin Kidney J ISSN: 2048-8505
Clinicopathological characteristics of patients with IgAN at the time of biopsy
| Clinical findings | |
|---|---|
| Age, years | 40 ± 13 (15–70) |
| Male, | 73 (66) |
| BMI, kg/m2 | 22.6 ± 3.5 |
| Current smoker, | 16 (14) |
| No. of antihypertensive medications, | 0.8 ± 1.0 |
| 0 | 61 (55) |
| 1 | 20 (18) |
| 2 | 19 (17) |
| 3 | 11 (10) |
| ACE-I/ARB, | 37 (33) |
| Diuretics, | 2 (2) |
| Corticosteroids, | 5 (5) |
| Diabetes mellitus, | 3 (3) |
| Hyperuricemia, | 54 (49) |
| Urinary protein excretion, g/day | 1.2 ± 1.8 (0.1–7.7) |
| eGFR, mL/min/1.73 m2 | 64 ± 26 (11–121) |
| GFR stage, | |
| G1 | 17 (15) |
| G2 | 47 (42) |
| G3a | 19 (17) |
| G3b | 13 (12) |
| G4, 5 | 15 (14) |
| Office blood pressure, mmHg | 122/73 |
| 24-h ABP, mmHg | 119/77 |
| Daytime ABP, mmHg | 121/79 |
| Nighttime ABP, mmHg | 111/70 |
| NDR of ABP | 0.90 |
| Histopathological findings, | |
| M1 | 35 (32) |
| E1 | 30 (27) |
| S1 | 83 (75) |
| T1/T2 | 20/17 (18/15) |
| Global glomerulosclerosis, % | 22 ± 21 |
| Segmental glomerulosclerosis, % | 7 ± 8 |
| Crescentic lesion present, | 66 (59) |
| Cellular/fibrocellular/fibrous, | 19(17)/51(46)/38(34) |
| PG, % | 35 ± 23 |
| H-grade I, | 48 (43) |
| H-grade II, | 32 (29) |
| H-grade III + IV, | 31 (28) |
Values are given as the mean ± SD (range) unless otherwise indicated.
BMI, body mass index; ACE-I, angiotensinogen-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; PG, the ratio of prognostic glomeruli to total obtained glomeruli according to the JC.
Comparison of the mean value and NDR of ABP according to the Oxford classification (n = 111)
| M0 ( | M1 ( | P-value | ||
| Daytime mean ABP | 93 ± 10 | 92 ± 12 | 0.727 | |
| Nighttime mean ABP | 84 ± 12 | 83 ± 13 | 0.648 | |
| NDR | 0.90 ± 0.08 | 0.90 ± 0.06 | 0.680 | |
| E0 ( | E1 ( | |||
| Daytime mean ABP | 93 ± 11 | 93 ± 10 | 0.861 | |
| Nighttime mean ABP | 84 ± 13 | 84 ± 11 | 0.841 | |
| NDR | 0.90 ± 0.07 | 0.90 ± 0.07 | 0.840 | |
| S0 ( | S1 ( | |||
| Daytime mean ABP | 94 ± 11 | 92 ± 10 | 0.597 | |
| Nighttime mean ABP | 85 ± 15 | 83 ± 12 | 0.636 | |
| NDR | 0.90 ± 0.07 | 0.90 ± 0.07 | 0.952 | |
| T0 ( | T1 ( | T2 ( | ||
| Daytime mean ABP | 91 ± 9 | 95 ± 10 | 98 ± 15a | 0.012 |
| Nighttime mean ABP | 82 ± 11 | 85 ± 12 | 92 ± 16a | 0.010 |
| NDR | 0.90 ± 0.07 | 0.89 ± 0.08 | 0.93 ± 0.07 | 0.210 |
| AA0 ( | AA1 ( | AA2 ( | ||
| Daytime mean ABP | 90 ± 10 | 93 ± 9 | 95 ± 13 | 0.240 |
| Nighttime mean ABP | 79 ± 11 | 84 ± 11 | 87 ± 16 | 0.052 |
| NDR | 0.88 ± 0.06 | 0.91 ± 0.07 | 0.92 ± 0.08 | 0.111 |
| AO0 ( | AO1 ( | AO2 ( | ||
| Daytime mean ABP | 89 ± 8 | 93 ± 12 | 95 ± 10 | 0.048 |
| Nighttime mean ABP | 81 ± 8 | 82 ± 14 | 88 ± 12 | 0.049 |
| NDR | 0.91 ± 0.04 | 0.89 ± 0.07 | 0.92 ± 0.08 | 0.129 |
Values are shown as the mean ± SD.
AA, arterial lesions; AO, arteriole lesions. aSignificant difference versus T0 using the Tukey–Kramer test.
Comparison of the mean value and NDR of ABP according to the Japanese classification (n = 111)
| C-grade I ( | C-grade II ( | C-grade III ( | P-value | |
| Daytime mean ABP | 88 ± 7 | 93 ± 9 | 96 ± 12a | 0.002 |
| Nighttime mean ABP | 79 ± 10 | 83 ± 11 | 88 ± 14a | 0.004 |
| NDR | 0.89 ± 0.08 | 0.90 ± 0.06 | 0.91 ± 0.08 | 0.470 |
| H-grade I ( | H-grade II ( | H-grade III/IV ( | ||
| Daytime mean ABP | 90 ± 9 | 92 ± 9 | 97 ± 13a | 0.021 |
| Nighttime mean ABP | 81 ± 11 | 84 ± 10 | 88 ± 15 | 0.087 |
| NDR | 0.90 ± 0.07 | 0.91 ± 0.07 | 0.90 ± 0.08 | 0.936 |
Values are shown as the mean ± SD.
aSignificant difference versus Grade I using the Tukey–Kramer test.
Multiple linear regression analyses for the daytime and nighttime ABP values
| IF/TA | PG | |||
|---|---|---|---|---|
| Standardized β | P-value | Standardized β | P-value | |
| Daytime ABP | ||||
| Model 1 | 0.338 | <0.001 | 0.275 | 0.004 |
| Model 2 | 0.312 | 0.001 | 0.252 | 0.009 |
| Model 3 | 0.284 | 0.047 | 0.139 | 0.300 |
| Model 4 | 0.321 | 0.022 | 0.177 | 0.173 |
| Model 5 | 0.329 | 0.024 | 0.176 | 0.180 |
| Nighttime ABP | ||||
| Model 1 | 0.318 | 0.001 | 0.242 | 0.011 |
| Model 2 | 0.263 | 0.006 | 0.181 | 0.064 |
| Model 3 | 0.242 | 0.092 | 0.072 | 0.533 |
| Model 4 | 0.294 | 0.040 | 0.110 | 0.408 |
| Model 5 | 0.313 | 0.035 | 0.110 | 0.411 |
Model 1 was unadjusted; Model 2 was adjusted for age and gender; Model 3 was adjusted for the eGFR and amount of urinary protein excretion; Model 4 was adjusted for covariates in Models 2 and 3; Model 5 was adjusted for covariates in Model 4 plus the use of antihypertensive medications (versus no medication). PG, the ratio of prognostic glomeruli to total obtained glomeruli according to the JC.